Another study performed both molecular profiling and drug screening in newly established primary cell culture models derived from patient tumor samples collected in an ongoing clinical trial to identify the mechanism of resistance by which DMG tumors evade MEK inhibitors (Izquierdo et al., 2022). Here, MAP2K7 is linked to neoplasm.